A Randomized Trial of Micronized Progesterone for the Prevention of Recurrent Preterm Birth

ABSTRACT

We sought to evaluate the effectiveness of daily oral micronized progesterone (MP) in preventing recurrent spontaneous preterm birth (RSPB) and whether MP increases maternal serum progesterone. We performed a pilot, single-center, randomized, double-blind, placebo-controlled trial in women with a prior preterm birth and current singleton gestation at 16 to 20 weeks (n = 33). The primary outcome was the rate of RSPB. Subjects were given either daily MP (400 mg) or placebo from 16 to 34 weeks. Serum progesterone was obtained at enrollment and in the late second/early third trimester. Pregnancy outcome data were collected. RSPB occurred in 5/19 (26.3%) in the MP group versus 8/14 (57.1%) in placebo group (p = 0.15). The mean age at delivery was 37.0 ± 2.7 weeks for the MP group versus 35.9 ± 2.6 weeks for the placebo (p = 0.3). Mean serum progesterone at 28 weeks was 122.6 ± 61.8 pg/mL for MP group versus 90.1 ± 38.7 pg/mL for placebo (p = 0.19). MP was associated with a trend toward a reduction in RSPB and an increase in the maternal serum progesterone. Although the primary outcome in this pilot study did not reach statistical significance, the results suggest a favorable trend meriting further investigation.

KEYWORDS

Preterm delivery - micronized - progesterone - recurrent - prevention

REFERENCES

• 1 March of Dimes Foundation .United States, Preterm Birth, Distribution of gestational age categories: US, 2006. 2010 Available at http://www.marchofdimes.com/peristats
• 2 Creasy R K. Preterm birth prevention: where are we?.  Am J Obstet Gynecol. 1993;  168 1223-1230
• 3 Meis P J, Klebanoff M, Thom E National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.  N Engl J Med. 2003;  348 2379-2385
• 4 Spong C Y. Prediction and prevention of recurrent spontaneous preterm birth.  Obstet Gynecol. 2007;  110 (2 Pt 1) 405-415
• 5 Simhan H N, Caritis S N. Prevention of preterm delivery.  N Engl J Med. 2007;  357 477-487
• 6 Murad F, Haynes J RC. Estrogens and Progestins. In: Goodman L S, Gilman A, Rall T W, Murad F, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 7th ed. New York: McGraw-Hill; 1985: 1412-1439
• 7 Schering-Plough research institute . FDA Product Information: Prometrium (Progesterone USP) 100 mg capsules.  Solvay Pharmaceuticals Inc. 1998; 
• 8 ACOG Committee on Practice Bulletins .Fetal Lung Maturity. ACOG Practice Bulletin No. 97. Obstetrics and Gynecology. 2008
• 9 Iams J D, Romero R. Preterm birth In: Gabbe S G, Niebyl J R, Simpson J L, eds. Obstetrics: Normal and Problem Pregnancies. 5th ed. Philadelphia: Churchill Livingston; 2007: 668-712
• 10 Goldenberg R L, Iams J D, Mercer B M NICHD MFMU Network et al. The preterm prediction study: the value of new vs standard risk factors in predicting early and all spontaneous preterm births.  Am J Public Health. 1998;  88 233-238
• 11 Rai P, Rajaram S, Goel N, Ayalur Gopalakrishnan R, Agarwal R, Mehta S. Oral micronized progesterone for prevention of preterm birth.  Int J Gynaecol Obstet. 2009;  104 40-43